Figure legends
Figure 1. SHR2554 drug–drug interaction study design: effect of coadministration of SHR2554 with rifampicin, compared with SHR2554 alone, on the pharmacokinetic profile of SHR2554 in Chinese healthy male volunteers.
Figure 2. Linear (A) and semilog (B) plasma concentration–time curves for SHR2554 after administration alone (300 mg) and coadministered with rifampicin (600 mg) in Chinese healthy volunteers. When ≥50% of the concentration data at a single time point were defined as BLQ, the mean concentration at that time point was set to BLQ. BLQ data were set to 0 on the linear scale and are not presented on the semilog scale. Error bars represent standard deviation. A Nominal time after dose: planned sampling time postdose. BLQ, below the limit of quantification.
Figure 3. Forest plot of the effect of coadministration of SHR2554 with rifampicin compared with SHR2554 alone on the exposure parameters of SHR2554 in Chinese healthy volunteers. AUC0–last, area under the concentration–time curve from time 0 to the last quantifiable concentration; AUC0–inf, area under the concentration–time curve from time 0 to infinity; CI, confidence interval; Cmax, maximum plasma concentration; GM, geometric mean.
Table1 Summary of subject baseline and demographic characteristics (full analysis set).